Objective. To evaluate the efficacy of treatment with pamidronate in reflex sympathetic dystrophy (RSD) refractory to previous treatment.
Reflex sympathetic dystrophy (RSD), also called complex regional pain syndrome type I, is a lengthy and painful affection with a protracted course and chronic sequelae in 20-40% of patients, represented by functional impairment anduor debilitating pain w1-4x. The classical medical treatments (calcitonin, physical treatment, sympathetic blockade, etc.) are not always effective and new therapies must be evaluated. Accelerated and enhanced bone resorption and turnover play a central pathophysiological role in RSD w5-10x. Bisphosphonates were proposed in the treatment of RSD due to their action as potent osteoclast-blocking agents w9-14x. Another property of bisphosphonates is the ability to inhibit afferent nerve fibres, from whose endings various neuropeptides are released following disease and trauma; these neuropeptides may contribute to the pain and trophic changes observed in RSD w7x. Pamidronate, a second-generation bisphosphonate, has shown efficacy in diverse pathological situations (hypercalcaemia, bone metastasis, Paget's disease) and also appears to be effective at various doses in RSD w11, 12, 14, 15x. The aims of our study were to evaluate the effectiveness of a standard dose of intravenous pamidronate in the treatment of RSD, and to find factors predictive of response to treatment.
Patients and methods
We included all patients affected by RSD who were seen at our consultations or hospitalized in our Department of Internal Medicine between 1 January 1993 and 30 June 1999. All patients were treated with pamidronate, with their verbal consent, after failure of classical medical treatment for at least 14 days. Diagnosis of RSD was based on Doury's criteria w4x. All patients complained of pain associated with allodynia anduor hyperpathia, tenderness and reduced range of motion, symptoms in an area much larger than the primary injury, and symptoms aggravated by physical activity of the affected extremity w2x. Swelling and changed skin temperature and skin colour were not always present, especially in the shoulder. All patients had a bone scintigraph suggestive of reflex sympathetic dystrophy. The use of non-steroidal anti-inflammatory drugs (NSAID), calcitonin, steroids and infiltrations was not authorized during the study. Twenty-nine cases of RSD were studied, comprising 10 men (34.5%) and 19 women (65.5%); the average age was 53.0 " 14.0 yr (range 14 -81 yr), without significant difference between the sexes wmen 53.6 " 11.6 yr; women 52.6 " 12.4 yrx.
The duration of the disease before treatment with pamidronate, was on average 41.89 " 38.90 weeks (range 2-163). For 20 patients wshoulder (16), knee (3) and wrist (1)x, the quantification of the reduction in amplitude was on average 45.258 " 15.08 (range 30-70). The RSD was localized in the upper limb in 58.6% of cases, and in the lower limb in 41.4% (Tables 1  and 2 ). A secondary aetiology was found in 93.2% of patients (n = 27) ( Tables 1 and 2 ). The treatments carried out before the use of pamidronate are mentioned in Tables 1 and 2 . Pamidronate was administered intravenously in 500 ml of glucose 5% over 4 h with a daily dose of 60 mg over a period of 3 consecutive days (a cumulative dose of 180 mg). The treatment was evaluated on days 15 and 45 after the beginning of pamidronate treatment. The treatment was considered to be effective if the pain disappeared completely (stopping of analgesics). The functional improvement was judged to be favourable if the increase in range of movement was more than 208 compared with the range of movement prior to treatment. The measurements of the delay in pain disappearance and the delay in functional improvement were analysed as continuous variables. Side-effects of pamidronate were noted.
We performed the statistical analysis using SPSS. All P values were two-sided, with a value of <0.05 considered to be statistically significant. The tests used in the univariate analysis were the Wilcoxon non-parametric test for comparison of averages, the Fisher exact test for comparison of percentages and the Pearson non-parametric test for correlations between variables. Logistic regression was used for multivariate analysis of categorical variables (functional improvement and disappearance of pain). 
Results
On day 15 after the beginning of the treatment, total pain disappearance was obtained in 17 patients (58.6%) and functional improvement was observed in nine cases (45% of 20). On the 45th day after the beginning of the treatment, total disappearance of pain was obtained in 25 patients (86.2%) and functional improvement was obtained in 14 out of 20 patients (70%) ( Table 3 ). The mean delay before pain disappearance was 19.96 " 14.4 days, without significant difference between the sexes (men 15 " 0 days, women 10 " 4.3 days; P = 0.079). The mean delay until functional improvement was 28.95 " 18.26 days, without significant difference between the sexes (men 32 " 11 days, women 28 " 20 days; P = 0.154). Functional improvement was faster in younger patients (r = 20.460; P = 0.0031). The aetiology of RSD varied according to age: trauma was more frequent in younger people (r = 20.459; P = 0.012).
The mean delay until functional improvement was shorter in patients with post-traumatic RSD (16.9 " 9.7 days) than in the other patients (34.5 " 18.4 days; P = 0.04). No correlation was found between age and disappearance of pain. Localization in the lower limb did not seem to be associated with faster functional improvement (r = 20.285; P = 0.14) and the disappearance of pain was not significantly related to its localization (r = 20.112; P = 0.58). Multivariate analysis did not reveal any factor predictive of response to treatment. Side-effects were observed in 20.7% (n = 6) of cases wfever 20.7% (n = 6), shivers 17.2% (n = 5) and diarrhoea 10.7% (n = 3)x.
Discussion
The natural course of RSD is lengthy and varies from 3 to 9 months w1-4x with chronic sequelae in about 30% of cases. This study, although imperfect because of the absence of a control group, gives objective evidence for the effectiveness of pamidronate in the treatment of RSD, as regards both pain disappearance and functional improvement. This series is comparable to published studies of the treatment of RSD with bisphosphonates (Table 4) as regards the age and sex ratio of the patients and the duration of the RSD. In contrast to the cases reported in other publications, 93.2% of the cases of RSD were secondary, and an aetiological agent was usually found in only 50-75% of the cases w14-16x. This is probably due to the fact that patients were seen in a department of internal medicine. Our study only considered cases of refractory RSD, and is the only one that has taken into account the total disappearance of pain and improvement in the range of movement. It provides evidence of a satisfactory response on day 45 (86.2% for pain and 70% for functional improvement). As in our series, no factor predictive of response to pamidronate was found in the study (11 patients) of Maillefert et al. w15x. Cortet et al. w14x have already demonstrated, in a series of 23 patients, significant effectiveness of intravenous pamidronate on pain, expressed as a reduction in the scores of pain scales on the 30th, 60th and 90th days after the beginning of the treatment; however, pamidronate was given in variable doses (60-180 mg). Maillefert et al. w15x noted an improvement in six of 11 cases with a dose of 30 mg of intravenous pamidronate per day for 3 days (a cumulative dose of 90 mg), expressed as a significant pain reduction on day 90. A recent article on the pooled data of these two studies is similar in its conclusions w16x. Adami et al. w17x reported, in an open, controlled factorial trial vs placebo, a very significant reduction in pain and local oedema in 62% of patients treated with intravenous alendronate at a daily dose of 7.5 mg on 3 non-consecutive days (days 0, 15 and 30). They also noted an increase in bone mass 6 weeks after the beginning of the treatment. Varenna et al. w18x observed a significant decrease in pain and clinical global improvement in 15 patients treated with clodronate compared with the placebo group (17 patients). Pamidronate appeared to be effective and well tolerated in the treatment of refractory RSD. However, a randomized, double-blind, controlled placebo study is necessary to confirm this. Use of pamidronate as the first-intention treatment for RSD can be proposed. However, there are two limiting factors: the cost of pamidronate and the need for intravenous administration.
